Brain Tumors: What Can DNA Tell Us?

Changes in Chromosome Caps May be A Marker for Tumor Aggression in Neurofibromatosis Type 1

Brain Tumors: What Can DNA Tell Us? | Johns Hopkins Medicine

Researchers at the Johns Hopkins Kimmel Cancer Center report that their study of tumor samples from people with the rare genetic syndrome neurofibromatosis type 1 (NF1) has uncovered novel molecular clues about which tumors are most ly to be aggressive in those with NF1. According to the researchers, the clues could advance the search for more customized and relevant treatments that spare patients exposure to treatments unly to work.

“Some NF1 tumors are hard to classify as benign or malignant,” says study leader Fausto Rodriguez, M.D., associate professor of pathology, oncology, and ophthalmology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. “Having another molecular marker to evaluate will help us make better predictions about the outcomes of treatment.”

A summary of the study was published online in the journal Acta Neuropathologica Communications on Aug. 28.

NF1 is caused by mutations in the NF1 gene. Although rare overall, occurring in about one in 3,000 people, it is among the most common so-called genetic syndromes. About half of all cases are inherited.

People with NF1 are predisposed to develop multiple tumors in the brain and along peripheral nerves throughout the body, just under the skin, and also are predisposed to form rarer tumors of the gastrointestinal tract, adrenal gland and other soft tissues.

The overall number of tumors per patient varies greatly, from several to hundreds over their lifetimes.

While most are slow-growing (low-grade) and benign, some benign peripheral nerve tumors (neurofibromas) develop into so-called malignant peripheral nerve sheath tumors (MPNST), which metastasize frequently, are challenging to treat and are a major cause of death in patients with NF1.

Over time, Rodriguez said he noticed that many of the high-grade, aggressive NF1 tumors he examined were lacking the protein ATRX, a loss associated with a cancer-specific biological process called ALT, short for alternative lengthening of telomeres. Co-investigator Christopher Heaphy, Ph.D.

, ALT expert and assistant professor of pathology and oncology at Johns Hopkins, explains that at the end of each chromosome in a cell’s nucleus, a sequence of six DNA “letters” is repeated up to 2,000 times to form a so-called telomere. “Telomeres are the plastic caps on the ends of shoelaces,” he says.

“They protect chromosomes from fraying or getting jumbled.”

Before a cell divides, it must duplicate its chromosomes, along with their telomeres, but the very tips of the telomeres can’t be replicated. So a few dozen DNA letters are lost each time a cell divides, making telomere length a stand-in for the age of a cell, says Heaphy.

Since cancer cells divide more frequently than most healthy cells, their telomeres shorten more quickly, putting the cell in danger of chromosomal instability, cell death and “genomic catastrophe,” says Heaphy.

To combat this, most cancer cells turn on a special enzyme called telomerase to maintain the length of their telomeres. (Carol Greider, Ph.D.

, the Daniel Nathans Professor and Director of Molecular Biology and Genetics at Johns Hopkins, won the 2009 Nobel Prize in Physiology or Medicine for her discovery of telomerase.)

“A subset of cancers, however, do not activate telomerase but use the ALT mechanism instead,” says Heaphy. ALT uses homologous recombination, a type of exchange of genetic material, to lengthen telomeres, but how exactly this happens remains under investigation.

To assess the importance of ALT in NF1 tumors, Rodriguez, Heaphy and colleagues used fluorescent probes that illuminated the telomeres to examine 426 tumor samples from 256 patients with NF1.

Overall, ALT was detected in 23 NF1-associated gliomas (32.9%). Of the ALT-positive tumors, 14 (60%) were high-grade, or aggressive, tumors, while only 9 of 47 low grade gliomas (19%) were ALT positive.

Among the 99 MPNST samples, 93 developed in patients known to have NF1. ALT was present in 15 of 148 (17%) patients, but ALT was almost entirely absent from the 77 neurofibromas studied and all other rarer tumors (46), except for two cases, which were both malignant.

“The data show that ALT is usually — although not always — associated with more aggressive tumors in patients with NF1,” says Rodriguez. “It’s also more ly to occur in gliomas than MPNSTs.”

Using the same assay, the team also assessed cells from tumors that were ALT-negative. They assessed the overall telomere lengths and compared them with those in non-cancerous cells within the same sample, and then scored as short, normal or long.

In the 183 ALT-negative neurofibromas assessed, all the telomere lengths were considered normal. By contrast, normal telomeres were found in only 57% and 50%, respectively, of the 30 ALT-negative gliomas and 30 ALT-negative MPNSTs tested. While altered telomere lengths were prevalent, abnormal telomeres tended to be too long in gliomas (40%), and too short in MPNSTs (47%).

Rodriguez says those differences could be used clinically to predict tumor aggressiveness, but he cautioned that the differences also could stem from variations in patient age, the fact that standard telomere lengths differ in various cell types, the timing of telomerase activation, or something else. Larger studies are needed, he adds, to rule out those possibly confounding factors.

Finally, the researchers analyzed correlations between telomere alterations and patient survival. Patients with gliomas survived longer if they were ALT-negative even when adjusting for age and grade, two important factors affecting outcome in brain tumors.

For patients with MPNSTs there was no statistically significant difference between those that were ALT-positive or negative.

However, among the whole group of MPNSTs, the researchers found that short telomeres appeared to provide a significant survival advantage, a finding they called “counterintuitive” and that remains unexplained.

“While ALT analysis is not yet a clinical test, surrogate markers such as ATRX loss, may be useful in NF1 patients as a prognostic indicator of more aggressive tumors and worse survival,” says Rodriguez.

In addition to Rodriquez and Heaphy, other researchers included Mindy Graham, Jacqueline Brosnan-Cashman, John Barber, Christine Davis, M. Adelita Vizcaino, Doreen Palsgrove, Caterina Giannini, Me Pekmezci, Sonika Dahiya, Murat Gokden, Michael Noë, Laura Wood, Christine Pratilas, Carol Morris, Allan Belzberg and Jaishri Blakeley.

The research was funded by Pilocytic/Pilomyxoid Research Fund, including Lauren’s First and Goal, and the Stick it to Brain Tumors Annual Women’s Ice Hockey Tournament; the Basic/Translational Science Investigator Award from the North American Neuroendocrine Tumor Society supported by the Neuroendocrine Tumor Research Foundation; a collaborative grant between the Wilmer Eye Institute and the King Khaled Eye Specialist Hospital in Riyadh, Saudi Arabia; Department of Defense grant W81XWH-18-1-0496; and National Institutes of Health grants 2T32CA009110-39A1 and P30 CA006973.

Source: https://ictr.johnshopkins.edu/news_announce/changes-in-chromosome-caps-may-be-a-marker-for-tumor-aggression-in-neurofibromatosis-type-1/

Nanoparticle Slips Suicide Gene into Pediatric Brain Cancer Cells

Brain Tumors: What Can DNA Tell Us? | Johns Hopkins Medicine

If you dispatch a suicide gene, you want to make sure that it bypasses healthy cells on its way to harmful cells, such as cancer cells.

What’s more, you want to make sure that the suicide gene is sent via a delivery system that treads lightly—especially if the suicide gene is meant to treat pediatric patients, who have relatively fragile immune systems.

Unfortunately, pediatric patients may have difficulty tolerating the most common gene delivery systems, which are derived from viruses.

To build a targetable and relatively innocuous delivery system, scientists based at the Johns Hopkins University School of Medicine turned to nanotechnology. Basically, they developed a library of poly(beta-amino ester) nanoparticles, or PBAEs. These tiny delivery vehicles consist of biodegradable, cationic polymers, and they self-assemble with nucleic acids.

According to a study (“Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies”) that appeared in the January issue of Nanomedicine: Nanotechnology, Biology and Medicine, the Johns Hopkins researchers used PBAEs to package and deliver the suicide gene herpes simplex virus type I thymidine kinase (HSVtk). Once HSVtk is delivered to a cancer cell, it makes an enzyme that helps restore the cell’s natural tumor suppression function, promoting apoptosis, the cell’s self-destruct mechanism.

To test their PBAEs, the Johns Hopkins researchers used them to transfect cells in mouse xenograft models of cancer, specifically, models that presented medulloblastoma (MB) and atypical teratoid/rhabdoid tumors (AT/RT). The researchers confirmed that their PBAE-delivered gene therapy made cancer cells more sensitive to ganciclovir, an antiviral drug.

Ganciclovir is commonly used in gene therapies that deliver an altered HSVtk gene to kill advanced melanoma cells and brain tumor cells. But such therapies typically rely on viral vectors.

“In vivo, PBAE-HSVtk treated groups had a greater median overall survival in mice implanted with AT/RT and MB,” the article’s authors wrote. “Our data provide proof of principle for using biodegradable PBAE nanoparticles as a safe and effective nanomedicine for treating pediatric CNS malignancies.”

The experiments showed that a combination of the suicide gene and ganciclovir delivered by intraperitoneal injection to mice killed more than 65% of the two types of pediatric brain tumor cells. The combination was deliberately transfected with the gene seven days after the nanoparticle therapy was used to deliver the genetic material.

Mice bearing an AT/RT-type tumor lived 20% longer after receiving the treatment—42 days, compared to 35 days for untreated mice. Those with a group 3 medulloblastoma-type tumor implanted in the brain lived 63% longer, surviving 31 days compared to 19 days for untreated mice.

The authors also indicated that PBAE nanoparticles formulated with plasmid DNA for intracellular gene delivery to pediatric brain cancer cells enabled >50% transfection in both cell lines tested. They also found that the nanoparticles preferentially targeted tumor cells over healthy cells.

The nanoparticles “can carry larger genes than what can be carried by a virus, and can carry combinations of genes,” emphasized Jordan Green, PhD, a co-corresponding author of the current study and an investigator at the Johns Hopkins Kimmel Cancer Center Bloomberg–Kimmel Institute for Cancer Immunotherapy. “It’s a platform that doesn’t have limitations on the cargo size being delivered, or limitations related to immunogenicity or toxicity. And, it is easier to manufacture than a virus.”

“It’s an exciting alternate way to be able to deliver gene therapy to a tumor in a selective fashion that targets only tumor cells,” added Eric Jackson, MD, another co-corresponding author and an associate professor of neurosurgery at the Johns Hopkins University School of Medicine. “Our idea now is to find other collaborators who may have a gene therapy that they think would work well to kill these tumors.”

Medulloblastoma and AT/RT are two of the most prevalent and deadly pediatric brain malignancies.

Traditional treatments, including radiation, can harm healthy tissue as well as the tumor, and can produce long-lasting developmental side effects in growing children, making it critical to find new therapies, Jackson noted.

Gene therapy that targets only cancer cells is a promising treatment avenue, but many gene therapy methods use a modified virus to deliver their therapeutic payloads of DNA, a method that may not be safe or suitable for pediatric use.

The mechanism that allows the PBAE nanoparticles to target tumor cells preferentially is still being investigated, but Green thinks “the chemical surface of the particle is ly interacting with proteins that are on the surface of certain types of cancer cells.”

“By making small chemical changes to the polymers that make up the nanoparticles, we can significantly change the cellular uptake into particular kinds of cancer cells, and the subsequent gene delivery to the cytosol, in a cell-specific way,” Green asserted.

“It should be noted that PBAEs are not restricted to delivering genes such as HSVtk,” the article’s authors added. “[These nanoparticles] have been validated as vectors for the delivery of other nucleic acids such as siRNA19 and miRNA24 as well.”

Jackson said that he hopes the nanoparticles can be used to deliver a variety of gene-based treatments—including therapies that alter the expression levels of genes, turn genes on and off altogether, or sensitize cells to other therapies—depending on the specifics of a patient’s tumor. “In some ways,” he remarked, “we’re still in the discovery phase of what genes to target” in medulloblastoma and AT/RT.

Source: https://www.genengnews.com/news/nanoparticle-slips-suicide-gene-into-pediatric-brain-cancer-cells/

Ludwig Cancer Research

Brain Tumors: What Can DNA Tell Us? | Johns Hopkins Medicine

Ludwig Johns Hopkins Co-director Bert Vogelstein and Ludwig Stanford Director Irv Weissman have won the 2019 Albany Medical Center Prize in Medicine and Biomedical Research.

Weissman is renowned for being the first to isolate and characterize a human tissue stem cell—the hematopoeitic stem cell.

Vogelstein is known for modeling the progressive mutational events underlying colorectal cancer and for being part of the team that first sequenced a cancer exome.

In a Science Translational Medicine study, researchers led in part by Ludwig Johns Hopkins Co-director Bert Vogelstein describe how a laboratory test using artificial intelligence tools has the potential to more accurately sort out which people with pancreatic cysts will go on to develop pancreatic cancers.

Ludwig Johns Hopkins’ Bert Vogelstein and his colleagues have developed several technologies in the past few years that have become the foundations for well-funded spinoff cancer diagnostics companies.

For example, CancerSEEK—liquid biopsy tech designed to screen for and detect at least eight different types of cancer at earlier stages—was recently spun out into a startup called Thrive Earlier Detection Corp.

(Subscription required)

In this interview, Ludwig Stanford investigator Maximilian Diehn discusses the new urine test method he and his team developed to detect bladder cancer, the benefit of urine-based tests compared with other bladder cancer detection methods, and the lihood that this approach could become widely adopted.

In a panel at the AACR Annual Meeting, Ludwig Johns Hopkins’ Nickolas Papadopoulos discussed the potential for liquid biopsies to help detect cancer earlier, but noted that much more research is needed. He also said that with detection, “it’s a difference of thinking proactively rather than reactively” in our response to cancer.

Ludwig MIT’s Angelika Amon is one of five scientists to receive a 2019 Breakthrough Prize in Life Sciences, given for transformative advances toward understanding living systems and extending human life. Amon was honored for her work on determining the consequences of aneuploidy, an abnormal chromosome number that results from mis-segregation of chromosomes during cell division.

Ludwig Johns Hopkins Co-director Bert Vogelstein shares a video analysis of the results, published in Science, of a study on whether mutations that drive malignant growth are the same or vary between primary tumors and their metastases.

A magnetic wire used to snag scarce and hard-to-capture tumor cells could prove to be a swift and effective tactic for early cancer detection, according to a Nature Biomedical Engineering study led by Ludwig Stanford’s Sam Gambhir. In pigs, the technique attracts 10-80 times more tumor cells than current blood-based cancer-detection methods.

A Ludwig Cancer Research study, published in the journal Cell, has uncovered an entirely novel mechanism by which cells enter a state of dormancy as tissues starved of oxygen become increasingly acidic. The study, led by Chi Van Dang, scientific director of the Ludwig Institute for Cancer Research, has potentially significant implications for cancer therapy

According to the Wikimedia Foundation, the most-referenced paper across English Wikipedia is a 2002 collection of more than 15,000 sequences of human and mouse genes by Robert Strausberg, now deputy scientific director at the Ludwig Institute for Cancer Research.

Ralph Weichselbaum, who is today director of the Ludwig Center at Chicago, and Ludwig Board member Samuel Hellman suggested somewhat controversially in 1995 that metastatic cancer could occupy an intermediate state between curable, localized tumors and lethal, systemic disease. Twenty-three years later, Weichselbaum, Hellman and colleagues have confirmed their “oligometastasis” hypothesis with a molecular analysis of tumors from patients treated for colorectal cancer.

As Ludwig MIT’s director Bob Weinberg once said: “If you live long enough, you will get cancer.” But why is cancer the beast that stalks us all? What is it about this disease that makes it inevitable? And why is it the price we must pay for many incredible evolutionary advances? To understand this issue, we need to go way back in our evolutionary history.

Ludwig’s Scientific Director Chi Van Dang expressed excitement about promising areas in the Lancet Oncology Commission report, which expands on recommendations of the Cancer Moonshot’s blue ribbon panel.

Richard Hynes of Ludwig MIT recently received the National Academy of Medicine’s David Rall Medal for his exceptional leadership as Chairman of the NAM/NAS Committee on Human Gene Editing. In this interview, he talks about his work and shares his perspective on how we can better engage with the public on important issues in science and medicine.

Ludwig Johns Hopkins Co-director Bert Vogelstein’s latest research unearthed a possible new method for detecting pancreatic cancer earlier using a liquid biopsy. This op-ed in Bloomberg gives an overview of Vogelstein’s research and other recent advances in early detection and prevention of cancer.

Ludwig Oxford’s Skirmantas Kriaucionis writes about the ways DNA base modifications add to the toolkit of critical gene-regulatory mechanisms. He outlines how researchers are just starting to explore how newly recognized epigenetic changes function in the genome.

Ludwig Johns Hopkins Co-director Bert Vogelstein illustrated the theme of the 2017 ACCR Annual Meeting—”Discover, Predict, Prevent, Treat”—at this year’s opening plenary.

He explained that the development of new therapies goes hand in hand with the development of new prevention strategies.

One key step is identifying the source of mutations for each type of cancer by improved molecular markers of disease using diagnostics such as liquid biopsies.

A recent study led in part by Ludwig Johns Hopkins Co-director Bert Vogelstein argues that random “mistakes” dividing cells make when copying their DNA account for nearly two-thirds of the mutations that cause cancer. This article, which includes input from Vogelstein, explains the methodology of the study and the implications of its findings.

The San Diego Union-Tribune covers Paul Mischel’s latest research in this article, which includes a video of Mischel’s lab.

In the video, Mischel describes how his team recently found that oncogenes “jump off” chromosomes onto extrachromosomal circles of DNA, driving tumor evolution and drug resistance.

If we better understood the mechanisms behind this activity, Mischel says, we might be able to develop more effective cancer treatments.

In this podcast, Paul Mischel fields questions about the recent study he led that upends old assumptions about cancer genes. Mischel’s findings will shift how cancer diversity and resistance are understood and studied.

A recent study led by Ludwig San Diego’s Paul Mischel is ly to change the way tumor evolution is understood by scientists and could ultimately lead to new ways to prevent and treat many malignancies. The Scientist reports on the findings and includes perspectives from several scientists not involved in the study.

Roeland Nusse of Ludwig Stanford and Stephen Elledge of Ludwig Harvard on winning the Breakthrough Prize in Life Sciences.

Nusse was noted for his discovery of the first Wnt gene and elucidation of its role in embryonic development, stem cells and the genesis of tumors.

Elledge was honored for his influential discoveries on how cells sense DNA damage and then engage their mechanisms of DNA repair—and how these processes relate to the development of cancer.

A blue ribbon panel, co-chaired by Tyler Jacks of Ludwig MIT and including Ludwig scientists George Demetri and Levi Garraway, released a report for the Cancer Moonshot that describes a set of 10 recommendations for accelerating cancer research to achieve the ambitious goal of making a decade’s worth of progress in 5 years.

Ludwig MIT scientist Tyler Jacks discusses recent advancements, market potential and ethnical questions related to CRISPR, a revolutionary gene-editing technology that has changed the cancer research landscape. Jacks and his lab have pioneered the use of CRISPR to construct in vivo models of human cancers.

Ludwig scientists speak about a blood-based screening test they’re developing to measure the a patient’s risk of colon cancer recurrence after surgery and determine whether subsequent chemotherapy is advisable. “This study shows that when we find tumor DNA circulating in the blood of cancer patients, recurrence is very ly,” says Nickolas Papadopoulos of Ludwig Johns Hopkins.

Ludwig scientists have shown that fragments of tumor DNA circulating in the blood can be used to better gauge the risk of colorectal cancer recurrence and the necessity of chemotherapy following surgery. Cancer Research UK reports that these findings could one day help doctors to better monitor and tailor treatments for their patients.

Ludwig Johns Hopkins Co-Directors Bert Vogelstein and Ken Kinzler share how they foster a sense of community among their team members. Costumes encouraged!

U.S. Vice President Joe Biden delivered an address at the AACR Annual Meeting, calling on researchers to accelerate progress against cancer by working more collaboratively and sharing data more freely. Ludwig Harvard director George Demetri was quoted in this article on the address, which also summarized key findings reported at the meeting.

Ludwig scientists Bert Vogelstein and Maximilian Diehn are quoted in an article about the increasing commercial interest in developing liquid biopsies to screen for cancer.

Ludwig Harvard director George Demetri talks to MSNBC’s Chris Matthews about what can be accomplished with Vice President Biden’s “Moonshot” initiative.

Ludwig Harvard director George Demetri was among the top cancer researchers who met with United States Vice President Joe Biden’s staff to discuss ideas for his cancer “moonshot” initiative announced during President Barack Obama’s State of the Union address.

The NIH has awarded three grants totaling $31.8 million toward the agency’s new 4D Nucleome Program—a collaborative research initiative aimed at better understanding how DNA is arranged within the cell’s nucleus in four dimensions—three-dimensional space plus time—and how changes in that nuclear organization affect human health and disease.

Patients with colon and other cancers who have a specific defect in genes needed for DNA repair are far more ly to respond to a new class of drugs such as Merck & Co’s Keytruda, which enlist the immune system to attack tumors, a new study has shown.

As sequencing costs reduce and computing power expands, opportunities abound for scientists to learn about the genetics of cancer.

Researchers in the National Institutes of Health Roadmap Epigenomics Project have now identified most of the chemical tags on DNA and its associated proteins that influence gene function and help define more than 100 different kinds of human cells. The knowledge of these so-called epigenetic modifications has already led to new insights into Alzheimer’s disease, cancer, and development.

Lab mice are tried-and-true stand-ins for human experimental subjects when it comes to medical studies, but sometimes what works for mice doesn’t work for men and women. Now a comparative survey of mouse and human genomes is taking a huge step toward figuring out why.

How Daniel K Ludwig’s formula for success has fuelled four decades – and counting – of top-notch cancer research.

Government funding, which has long supported the bulk of basic scientific research, is increasingly threatened in the U.S. If we hope to capitalize on the remarkable progress made in molecular medicine over the past few decades to solve such intractable problems as cancer, diabetes, and other diseases, something will have to change—and soon.

American science is increasingly starved of funds. In 2013, the U.S. National Institutes of Health was forced to slash $1.5 billion from its budget. As a consequence, only one in seven biomedical researchers who apply for an NIH grant today will receive one — marking an historic low.

Six facilities for cancer studies launched in 2006 by New York-based charity Ludwig Cancer Research will each receive $90-million more from the parent group to pursue unrestricted research into how the disease starts, spreads, and can be stopped.

An American shipping magnate’s trust will announce on Monday one of the largest philanthropic gifts to support cancer research: more than half a billion dollars to be divided equally among six institutions, including Harvard Medical School and the Massachusetts Institute of Technology.

Stanford has received a vast sum of money to study a tiny population of deadly cancer cells, a gift that could help combat the heartbreak of phoenix disease recurrence.

Johns Hopkins University scientists will share in one of the largest one-time philanthropic gifts for cancer research ever made, $540 million aimed at preventing and curing the disease, officials are scheduled to announce today.

MIT and Harvard each received $90 million from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig, which will provide funding to transform basic research on metastasis, the process by which cancer cells spread from a primary tumor to distant sites in the body.

A trust fund created by billionaire shipping tycoon Daniel K. Ludwig ends today with a bang and a gift to research. Six U.S. medical centers will receive $540 million—$90 million each—from the fund to endow cancer studies in perpetuity.

Scientists from the Ludwig Institute for Cancer Research and the Karolinska Institutet report the development of an improved method for analyzing the genes expressed within a single cell. They say their finding will be relevant for everything from basic research to future cancer diagnostics.

Some junk is worth keeping. Non-coding, or junk, mouse DNA contains vast amounts of information vital to gene function—and those regulatory functions take up much more space on the genome than the all-important coding segments.

Keep up with all the leading-edge research from Ludwig scientists around the globe. Sign up for our weekly e-mail, quarterly newsletter and periodic organizational updates.

Source: https://www.ludwigcancerresearch.org/news-articles-programs/cancer-genomics/